Cancer of the appendix differs from colorectal cancer after all

Share this article:

The same chemotherapy used for colon cancer is also used for cancer of the appendix, which is part of the colon, but this approach has proven to be largely ineffective. Now, gene expression profiling for appendiceal cancer has demonstrated that the disease is, in fact, quite distinct from colorectal cancer, and may require different treatment.

A rare malignancy affecting approximately 2,500 people per year in the United States, cancer of the appendix has the propensity to metastasize throughout the peritoneal cavity. Peritoneal metastases from appendiceal cancer and from colon cancer are both addressed with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC, in which heated chemotherapy is placed directly into the abdominal cavity at the time of surgery).

This approach shows great promise, according to Edward A. Levine, MD, chief of the surgical oncology service at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, and coauthor of the gene expression profiling study, published in Journal of the American College of Surgeons. However, many HIPEC patients experience cancer recurrence.

In order to better predict oncologic outcomes, Levine and colleagues analyzed global gene expression in 41 tissue samples of peritoneal metastases (26 appendiceal and 15 colorectal) taken from persons undergoing HIPEC with complete cytoreduction and more than 3 years of follow-up. They found three distinct phenotypes, two of which consisted of predominantly low-grade appendiceal samples and one consisting of predominantly colorectal samples. Genetic signatures predicted survival of low-risk vs high-risk appendiceal cancer and low-risk appendiceal cancer vs colon primary cancer.

Having confirmed the unique biology of appendiceal cancer, Levine's team suggested that basing treatment for such lesions on colon cancer regimens may be unwarranted, and that a fresh therapeutic approach to cancer of the appendix is needed. The newly identified phenotypes could lead to more effective treatments for both diseases.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.